Evidence map›Paper›PMID 35257069›Full record

ArticleKidney international reports2022

A Diverse Spectrum of Immune Complex- and Complement-Mediated Kidney Diseases Is Associated With Mantle Cell Lymphoma.

Nicole K Andeen, Shahad Abdulameer, Vivek Charu, Jonathan E Zuckerman, Megan Troxell, Neeraja Kambham, Charles E Alpers, Behzad Najafian, Roberto F Nicosia, Kelly D Smith and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 2 countries.

Nicole K AndeenDepartment of Pathology, Oregon Health & Science University, Portland, Oregon, USA.
Shahad AbdulameerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Vivek CharuDepartment of Pathology, Stanford University, Stanford, California, USA.
Jonathan E ZuckermanDepartment of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA.
Megan TroxellDepartment of Pathology, Stanford University, Stanford, California, USA.
Neeraja KambhamDepartment of Pathology, Stanford University, Stanford, California, USA.
Charles E AlpersDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Behzad NajafianDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Roberto F NicosiaDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Kelly D SmithDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Vanderlene L KungDepartment of Pathology, Oregon Health & Science University, Portland, Oregon, USA.
Rupali S AvasareDivision of Nephrology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
Anusha VallurupalliCenter for Hematologic Malignancies, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
J Ashley JeffersonDivision of Nephrology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Douglas HecoxRenal Care Consultants, Medford, Oregon, USA.
Leah SwetnamNephrology, Kaiser Permanente, Portland, Oregon, USA.
Michifumi YamashitaDepartment of Pathology, Cedars Sinai Medical Center, Los Angeles, California, USA.
Mercury LinDepartment of Pathology, Cedars Sinai Medical Center, Los Angeles, California, USA.
Mei Lin BissonnetteDepartment of Pathology, St Paul's Hospital, The University of British Columbia, Vancouver, British Columbia, Canada.
Shreeram AkileshDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Jean HouDepartment of Pathology, Cedars Sinai Medical Center, Los Angeles, California, USA.
University of Washington · USOregon Health & Science University · USCedars-Sinai Medical Center · USStanford University · USKaiser Permanente Center for Health Research · USUniversity of British Columbia · CAUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: There are limited reports on kidney biopsy findings in patients with mantle cell lymphoma (MCL). Methods: We initiated a multi-institutional, retrospective review of kidney biopsy findings in patients with active and treated MCL. Results: A total of 30 patients with MCL and kidney biopsies were identified, with a median age of 67 (range 48-87) years, 73% of whom were men. A total of 20 patients had active MCL at the time of biopsy, of whom 14 (70%) presented with acute kidney injury (AKI), proteinuria and/or hematuria, and biopsy findings potentially attributable to lymphoma. Of the 14, 11 had immune complex (IC) or complement-mediated (C3) disease including proliferative glomerulonephritis (GN) with monotypic Ig deposits (PGNMID [2]), C3GN, (2), secondary membranous nephropathy (MN [3]), tubular basement membrane (TBM) deposits (2), and modest lupus-like GN (2). Lymphomatous infiltration was present in 8 of the 20 patients, 5 with coincident IC or C3 lesions. A total of 6 patients with available follow-up were treated for MCL, all with clinical remission of GN (2 PGNMID, 2 C3GN, and 2 MN). Conclusion: MCL is associated with diverse monoclonal and polyclonal glomerular and extra-glomerular IC and C3 disease. For patients with active MCL and kidney dysfunction requiring biopsy, 70% had findings due or potentially due to lymphoma, including 55% with IC or C3 disease and 40% had lymphomatous kidney infiltration. IC and C3GN in the setting of active MCL was responsive to lymphoma-directed therapy.

Indexed as

glomerulonephritiskidney biopsylymphomaMantle cell lymphomaMGRSrenal pathology

Identifiers

PMID35257069
PMCPMC8897291
OpenAlexW4200236941

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.